ArriVent BioPharma reported that firmonertinib failed to delay tumor progression in a Phase 3 study in exon 20-mutated lung cancer, sending the company’s stock down. The setback renews pressure on the increasingly crowded EGFR exon 20 inhibitor space. The result is a critical clinical validation checkpoint for a drug the company previously framed as a candidate for broader uptake after earlier development steps. For investors, the primary endpoint miss materially changes expected timelines and capital planning. Strategically, the data will likely refocus ArriVent on alternative development paths, partnerships, or program reprioritization within its pipeline.